Director linked to Suvretta receives 43,000 Veradermics (MANE) options

Rhea-AI Filing Summary

Veradermics, Inc. reported that director David Matthew Friedman was granted a stock option covering 43,000 shares of common stock at an exercise price of $17 per share on February 3, 2026. The option is scheduled to become fully vested and exercisable on February 3, 2027.

According to the disclosure, Friedman, an employee of Suvretta Capital Management, LLC, is holding this award for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. He disclaims beneficial ownership of the option, while the Funds and Suvretta Capital may be deemed to have an indirect pecuniary interest through rights to receive director compensation linked to his board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Friedman David Matthew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	43,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 43,000 shares (Direct)

Footnotes (1)

1. Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as an employee of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service. This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friedman David Matthew

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	02/03/2026		A		43,000(1)		(2)	02/03/2036	Common Stock	43,000	$0	43,000	D

Explanation of Responses:

1. Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as an employee of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service.

2. This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veradermics (MANE) report for David Matthew Friedman?

Veradermics reported a grant of stock options to director David Matthew Friedman for 43,000 shares of common stock at an exercise price of $17 per share on February 3, 2026, in connection with his service on the company’s Board of Directors.

When do David Matthew Friedman’s Veradermics (MANE) options vest and expire?

The reported Veradermics stock option for 43,000 shares becomes fully vested and exercisable on February 3, 2027, which is the first anniversary of the vesting commencement date, and is scheduled to expire on February 3, 2036, providing a long-dated equity incentive.

What is the exercise price of the Veradermics (MANE) stock option granted to Friedman?

The stock option granted in favor of David Matthew Friedman has an exercise price of $17 per share for Veradermics common stock. This means the holder can purchase up to 43,000 shares at $17 each once the option is fully vested and exercisable.

Who economically benefits from David Matthew Friedman’s Veradermics (MANE) option grant?

The option is held by Friedman for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. Suvretta Capital Management, as investment manager, and the Funds may be deemed to have an indirect pecuniary interest, while Friedman disclaims beneficial ownership of the award.

Is David Matthew Friedman’s ownership of the Veradermics (MANE) option direct or indirect?

The Form 4 classifies the 43,000 Veradermics stock options as held with direct ownership. However, a footnote explains Friedman holds them for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., and disclaims beneficial ownership in favor of those Funds and Suvretta Capital.

What role does Suvretta Capital have in the Veradermics (MANE) option grant?

Suvretta Capital Management, LLC is the investment manager to the Averill funds that benefit from the option grant. It may be deemed to have an indirect pecuniary interest because it has rights to receive the benefit of director compensation tied to Friedman’s Veradermics board service.